PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : A61K 39/395, C12N 15/00, 5/00 C07K 13/00, 15/04	A1	(11) International Publication Number: **WO 89/09622** (43) International Publication Date: 19 October 1989 (19.10.89)

(21) International Application Number: PCT/US89/01578

(22) International Filing Date: 13 April 1989 (13.04.89)

(30) Priority data:
181,862   15 April 1988 (15.04.88)   US

(71) Applicant: PROTEIN DESIGN LABS, INC. [US/US]; 3181 Port Drive, Palo Alto, CA 94304 (US).

(72) Inventor: QUEEN, Cary, L. ; 886 Roble Avenue, Menlo Park, CA 94025 (US).

(74) Agent: HANN, James, F.; Townsend and Townsend, One Market Plaza, 2000 Steuart Tower, San Francisco, CA 94105 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent),

NL (European patent), NO, SE (European patent).

Published
With international search report.

---

(54) Title: IL-2 RECEPTOR-SPECIFIC CHIMERIC ANTIBODIES

(57) Abstract

Chimeric antibodies specifically reactive with human IL-2 receptors are prepared employing recombinant DNA technology for use in, e.g., treatment of T-cell mediated disorders.

IL-2 RECEPTOR-SPECIFIC CHIMERIC ANTIBODIES

Field of the Invention

The present invention relates generally to the
combination of recombinant DNA and monoclonal antibody
technologies for developing novel therapeutic and other
agents and, more particularly, to the production of chimeric
antibodies specific for the human interleukin-2 receptor and
the use of such chimeric antibodies in treating T-cell
mediated human disorders.

Background of the Invention

In mammals, the immune response is mediated by two
types of cells that interact specifically with foreign
material, i.e., antigens. One of these cell types, B-cells,
are responsible for the production of antibodies. The second
cell class, T-cells, include a wide variety of cellular
subsets controlling the in vivo function of both B-cells and
a wide variety of other hematopoietic cells, including T-
cells.

One way in which T-cells exert this control is
through the production of a lymphokine known as interleukin-2
(IL-2), originally named T-cell growth factor. IL-2's prime
function appears to be the stimulation and maintenance of T-
cells. Indeed, some immunologists believe that IL-2 may be
at the center of the entire immune response (see, Farrar, J.,
et al., Immunol. Rev. 63:129-166 (1982), which is
incorporated herein by reference).

To exert its biological effects, IL-2 interacts
with a specific high-affinity membrane receptor (Greene, W.,
et al., Progress in Hematology XIV, E. Brown, ed., Grune and
Statton, New York (1986), at pgs. 283 ff). The human IL-2
receptor is a complex glycoprotein, with one chain 55kD in
size (Leonard, W. et al., J. Biol. Chem. 260:1872 (1985)). A
gene encoding this protein has been isolated, and predicts a
272 amino acid peptide, including a 21 amino acid signal
peptide, (see, Leonard, W. et al., Nature 311: 626 (1984)).

Much of the elucidation of the human IL-2 receptor's structure and function is due to the development of specifically reactive monoclonal antibodies. In particular, one monoclonal antibody, known as anti-Tac, (Uchiyama et al., J. Immunol. 126:1393 (1981)) has shown that IL-2 receptors can be detected on T-cells, but also on cells of the monocyte-macrophage family, Kupffer cells of the liver, Langerhans' cells of the skin and, of course, activated T-cells. Importantly, resting T-cells, B-cells or circulating machrophages typically do not display the IL-2 receptor (Herrmann, et al., J. Exp. Med. 162:1111 (1985)).

The anti-Tac monoclonal antibody has also been used to define lymphocyte functions that require IL-2 interaction, and has been shown to inhibit various T-cell functions, including the generation of cytotoxic and suppressor T lymphocytes in cell culture. Also, based on studies with anti-Tac, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell leukemia.

More recently, the IL-2 receptor has been shown to be an ideal target for novel therapeutic approaches to T-cell mediated diseases. The anti-Tac monoclonal antibody can be used either alone or as an immunoconjugate (e.g., with Ricin A, isotopes and the like) to effectively remove cells bearing the IL-2 receptor. These agents can, for example, theoretically eliminate IL-2 receptor-expressing leukemic cells, certain B-cells, or activated T-cells involved in a disease state, yet allow the retention of mature normal T-cells and their precursors to ensure the capability of mounting a normal T-cell immune response as needed. In general, other T-cell specific agents can destroy essentially all peripheral T-cells, which limits therapeutic efficacy. Overall, the use of monoclonal antibodies specific for the IL-2 receptor can be expected to have therapeutic utility in autoimmune diseases, organ transplantation and any unwanted response by activated T-cells. Indeed, clinical trials have been initiated (see, generally, Waldman, T., Science 232:727-732 (1986), which is incorporated herein by reference).

Unfortunately, the use of the anti-Tac monoclonal antibody has certain drawbacks, particularly in repeated therapeutic regimens. As a mouse monoclonal, it does not fix human complement well, whereas a human equivalent may be more efficient.

More importantly, however, anti-Tac monoclonal antibody contains substantial murine amino acid sequences that will be antigenic when injected into a human patient. Numerous studies have shown that the immune response elicited by a patient against the nonbinding portion of an injected mouse monoclonal antibody can be quite strong, essentially eliminating the antibody's therapeutic utility after an initial treatment. As increasing numbers of different mouse monoclonal antibodies can be expected to be developed to treat various diseases, after the first and second treatments with different mouse monoclonal antibodies, subsequent treatments can be dangerous in themselves.

Thus, there is a need for improved forms of the anti-Tac monoclonal antibody that are substantially less antigenic, yet easily and economically produced in a manner suitable for therapeutic formulation. The present invention fulfills these needs.

Summary of the Invention

The present invention provides novel compositions useful in the treatment of T-cell mediated human disorders, the compositions containing a chimeric antibody specifically capable of binding to human IL-2 receptors, such as at the epitope bound by the anti-Tac monoclonal antibody. The IL-2 chimeric antibody can have two pairs of light chain/heavy chain complexes, wherein at least one pair has chains comprising mouse variable regions joined with human constant region segments, with or without naturally-associated J and D segments.

The chimeric antibodies, or binding fragments thereof, of the present invention may be produced by a variety of recombinant DNA techniques, with ultimate expression in transfected cells, preferably immortalized

4

eukaryotic cells, such as myeloma or hybridoma cells.
Polynucleotides comprising a first sequence coding for a
human immunoglobulin constant region and a second sequence
coding for the desired mouse immunoglobulin variable or
hypervariable region can be produced synthetically or by
5 combining appropriate cDNA and genomic DNA segments.

When the chimeric antibodies are complexed with a
cytotoxic agent, such as a radionuclide, a ribosomal
inhibiting protein or a cytotoxic agent active at cell
surfaces, the compounds will be particularly useful in
10 treating T-cell mediated disorders. These compounds can be
provided in a pharmaceutically accepted dosage form, which
will vary depending on the mode of administration.

15

20

25

30

35

BRIEF DESCRIPTION OF THE FIGURES

 Figure 1 depicts the DNA coding sequence and putative amino acid sequence of the V and J regions of the anti-Tac light chain.

 Figure 2 depicts the DNA coding sequence and putative amino acid sequence of the V and J regions of the anti-Tac heavy chain.

 Figures 3-10 are schematic diagrams of the plasmids utilized to demonstrate the present invention.

 Figure 11 represents an overview of a preferred strategy for preparation of V and J regions for insertion into plasmids.

6

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, DNA
sequences encoding mouse variable/human constant region
chimeric antibodies capable of binding epitopes on human IL-2
receptors are provided. When placed in expression vectors
5   and suitable hosts, large quantities of chimeric antibodies
can be produced. Preferably, the chimeric antibodies will
have substantially the same binding profile or
characteristics as (e.g., be cross-reactive or capable of
blocking) the binding of the anti-Tac monoclonal antibody,
10   such as antibodies produced by the myeloma cell line
deposited with the A.T.C.C. and designated accession number
CRL 9688. These chimeric antibodies find use, for example,
in the treatment of T-cell mediated disorders in human
patients.

15   The basic immunoglobin structural unit is known to
comprise a tetramer. Each tetramer is composed of two
identical pairs of polypeptide chains, each pair having one
"light" (about 25kD) and one "heavy" chain (about 50-70kD).
The NH_2-terminus of each chain begins a variable region of
20   about 100 to 110 or more amino acids primarily responsible
for antigen recognition. The COOH terminus of each chain
defines a constant region primarily responsible for effector
function.

Light chains are classified as either kappa or
25   lambda. Heavy chains are classified (and subclassified) as
gamma, mu, alpha, delta, or epsilon, and define the
immunoglobulin's isotype as IgG, IgM, IgA, IgD and IgE,
respectively. Within light and heavy chains, the variable
and constant regions are joined by a "J" region of about 12
30   or more amino acids, with the heavy chain also including a
"D" region of about 12 more amino acids. (See, generally,
Fundamental Immunology, Ed. Paul, W. Chapter 7, pgs. 131-166,
Raven Press, N.Y. (1984), which is incorporated herein by
reference.)

35   Chimeric antibodies are antibodies whose light and
heavy chain genes have been constructed, typically by genetic
engineering, from immunoglobulin gene segments belonging to

different species. For example, the variable (V) segments of the genes for a mouse monoclonal antibody may be joined to human constant (C) segments, such as γ_1, and γ_3. A preferred therapeutic chimeric antibody is thus a hybrid protein consisting of the V or antigen-binding domain from a mouse

5   antibody and the C or effector domain from a human antibody, although other mammalian species may be used.

Human chimeric antibodies have at least three potential advantages over mouse antibodies for use in human therapy:

10   1)   Because the effector portion is human, it may interact better with the other parts of the human immune system (e.g., destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity

15   (ADCC)).

2)   The human immune system should not recognize the C region of the chimeric antibody as foreign, and therefore the antibody response against an injected chimeric antibody should be less than against a

20   totally foreign mouse antibody.

3)   Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal antibodies (Shaw, D. et al., J. Immunol. 138:4534-4538

25   (1987)). It is possible that injected chimeric antibodies will have a half-life more like that of human antibodies, allowing smaller and less frequent doses to be given.

30   In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain variable or hypervariable regions from the anti-Tac monoclonal antibody. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate

35   constant regions, such as human gamma heavy chain regions or human kappa light chain regions. The preferred variable region DNA sequences, which on expression code for the

polypeptide chains comprising the anti-Tac light and heavy
chain variable regions (with naturally-associated J regions),
are shown in Figures 1 and 2, respectively. Due to codon
degeneracy and non-critical amino-acid substitutions, other
DNA sequences can be readily substituted for those sequences,
5   as detailed below.

The DNA segments will typically further include an
expression control DNA sequence operably linked to the
chimeric antibody coding sequences, including naturally-
associated or heterologous promoter regions. Preferably, the
10 expression control sequences will be eukaryotic promoter
systems in vectors capable of transforming or transfecting
eukaryotic host cells. Once the vector has been incorporated
into the appropriate host, the host is maintained under
conditions suitable for high level expression of the
15 nucleotide sequences, and, as desired, the collection and
purification of the light chains, heavy chains, light/heavy
chain dimers or intact chimeric antibodies may follow.

It is well known that native forms of "mature"
immunoglobulins will vary somewhat in terms of length by
20 deletions, substitutions, insertions or additions of one or
more amino acids in the sequences. Thus, both the variable
and constant regions are subject to substantial natural
modification, yet are "substantially identical" and still
capable of retaining their respective activities. Human
25 constant region DNA sequences can be isolated in accordance
with well known procedures from a variety of human cells, but
preferably immortalized B-cells. Suitable source cells for
the DNA sequences and host cells for expression and secretion
can be obtained from a number of sources, such as the
30 American Type Culture Collection ("Catalogue of Cell Lines
and Hybridomas," Fifth edition (1985) Rockville, Maryland,
U.S.A., which is incorporated herein by reference).

In addition to these naturally-occurring forms of
immunoglobulin chains, "substantially identical" modified
35 heavy and light chains can be readily designed and
manufactured utilizing various recombinant DNA techniques
well known to those skilled in the art. For example, the

chains can vary from the naturally-occurring sequence at the
primary structure level by several amino acid substitutions,
terminal and intermediate additions and deletions, and the
like. Alternatively, polypeptide fragments comprising only a
portion (usually at least about 60-80%, typically 90-95%) of

5   the primary structure may be produced, which fragments
possess one or more immunoglobulin activities (e.g.,
complement fixation activity), while exhibiting lower
immunogenicity. In particular, it is noted that like many
genes, the immunoglobulin-related genes contain separate

10   functional regions, each having one or more distinct
biological activities. These may be fused to functional
regions from other genes (e.g., enzymes, see, commonly
assigned U.S.S.N. 132,387, filed Dec. 15, 1987, which is
incorporated herein by reference) to produce fusion proteins

15   (e.g., immunotoxins) having novel properties. In general,
modifications of the genes may be readily accomplished by a
variety of well-known techniques, such as site-directed
mutagenesis (see, Gillman and Smith, Gene 8:81-97 (1979);
Roberts, S. et al, Nature 328:731-734 (1987); and U.S. Patent

20   no. 4,703,008, all of which are incorporated herein by
reference). Preferred DNA segments encoding variable regions
of the present invention will typically be substantially
homologous to the sequences of Figures 1 and 2 (i.e., capable
of hybridizing to the sequences under stringent conditions of

25   low salt and high temperature), most preferrably at least
about 90-95% homologous or more.
          The nucleic acid sequences of the present invention
capable of ultimately expressing the desired chimeric
antibodies can be formed from a variety of different

30   polynucleotides (genomic or cDNA, RNA, etc.) and components
(e.g., V, J, D, and C regions), as well as by a variety of
different techniques. Joining appropriate genomic sequences
is presently the most common method of production, but cDNA
sequences may also be utilized (see, European Patent

35   Application Nos. 85102655.8, 85305604.2, 84302368.0 and
85115311.4, as well as PCT Application Nos. GB85/00392 and
US86/02269, all of which are incorporated herein by

reference).

          As stated previously, the DNA sequences of the
present invention (typcially at least about 30 contiguous
nucleotides encoding 10 amino acids from the sequences in
Figures 1 and 2) will be expressed in hosts after the
5   sequences have been operably linked to (i.e., positioned to
ensure the functioning of) an expression control sequence.
These expression vectors are typically replicable in the host
organisms either as episomes or as an integral part of the
host chromosomal DNA. Commonly, expression vectors will
10   contain selection markers, e.g., tetracycline or neomycin, to
permit detection of those cells transformed with the desired
DNA sequences (see, e.g., U.S. Patent 4,704,362, which is
incorporated herein by reference).

          E. coli is one prokaryotic host useful particularly
15   for cloning the DNA sequences of the present invention.
Other microbial hosts suitable for use include bacilli, such
as Bacillus subtilus, and other enterobacteriaceae, such as
Salmonella, Serratia, and various Pseudomonas species. In
these prokaryotic hosts, one can also make expression
20   vectors, which will typically contain expression control
sequences compatible with the host cell (e.g., an origin of
replication). In addition, any number of a variety of well-
known promoters will be present, such as the lactose promoter
system, a tryptophan (trp) promoter system, a beta-lactamase
25   promoter system, or a promoter system from phage lambda. The
promoters will typically control expression, optionally with
an operator sequence, and have ribosome binding site
sequences and the like, for initiating and completing
transcription and translation.
30   Other microbes, such as yeast may also be used for
expression. Saccharomyces is a preferred host, with suitable
vectors having expression control sequences, such as
promoters, including 3-phosphoglycerate kinase or other
glycolytic enzymes, and an origin of replication, termination
35   sequences and the like as desired.
          In addition to microorganisms, mammalian tissue
cell culture may also be used to produce the polypeptides of

the present invention (see, Winnacker, "From Genes to
Clones," VCH Publishers, N.Y., N.Y. (1987), which is
incorporated herein by reference). Eukaryotic cells are
actually preferred, because a number of suitable host cell
lines capable of secreting intact immunoglobulins have been
developed in the art, and include the CHO cell lines, various
COS cell lines, HeLa cells, myeloma cell lines, etc, but
preferably transformed B-cells or hybridomas. Expression
vectors for these cells can include expression control
sequences, such as an origin of replication, a promoter, an
enhancer (Queen, C. et al., Immunol. Rev. 89:49-68 (1986),
which is incorporated herein by reference), and necessary
processing information sites, such as ribosome binding sites,
RNA splice sites, polyadenylation sites, and transcriptional
terminator sequences. Preferred expression control sequences
are promoters derived from immunoglobulin genes, SV40,
Adenovirus, Bovine Papilloma Virus, and the like.

The vectors containing the DNA segments of interest
(e.g., the heavy and light chain encoding sequences and
expression control sequences) can be transferred into the
host cell by well-known methods, which vary depending on the
type of cellular host. For example, calcium chloride
transfection is commonly utilized for prokaryotic cells,
whereas calcium phosphate treatment may be used for other
cellular hosts. (See, generally, Maniatis et al., Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Press,
(1982), which is incorporated herein by reference.)

Once expressed, the whole chimeric antibodies,
their dimers, or individual light and heavy chains of the
present invention can be purified according to standard
procedures of the art, including ammonium sulfate
precipitation, fraction column chromatography, gel
electrophoresis and the like. (See, generally, Scopes, R.,
Protein Purification, Springer-Verlag, N.Y. (1982).) Once
purified, partially or to homogeneity as desired, the
polypeptides may then be used therapeutically or in
developing and performing assay procedures, immunofluorescent
stainings, and the like. (See, generally, Immunological

12

Methods, Vols. I and II, Eds. Lefkovits and Pernis, Academic
Press, New York, N.Y. (1979 and 1981).)

The chimeric antibodies of the present invention
will typically find use individually in treating a T-cell
mediated disease state. Generally, where the cell linked to
5   a disease has been identified as IL-2 receptor bearing, then
the chimeric antibodies are suitable (see, U.S.S.N. 7-
085,707, entitled "Treating Human Malignancies and
Disorders," which is incorporated herein by reference).

For example, typical disease states suitable for
10   treatment graft versus host disease and most patients
undergoing an organ transplant, such as heart, lungs,
kidneys, liver, etc. Other diseases include Type I diabetes,
multiple sclerosis, rheumatoid arthritis, Lupus
erythematosus, and Myasthenia Gravis.

15   The antibodies of the present invention may also be
used in combination with other antibodies, particularly human
chimeric antibodies or human monoclonal antibodies reactive
with other markers on cells responsible for the disease. For
example, suitable T-cell markers can include those grouped
20   into the so-called "Clusters of Differentiation," as named by
the First International Leukocyte Differentiation Workshop,
Leukocyte Typing, Eds. Bernard, et al., Springer-Verlag, N.Y.
(1984), which is incorporated herein by reference.

The chimeric antibodies can also be used as
25   separately administered compositions given in conjunction
with chemotherapeutic or immunosuppressive agents.
Typically, the agents will include a cephalosporin or a
purine analog (e.g., methotrexate, 6-mercaptopurine, or the
like), but numerous additional agents (e.g.,
30   cyclophosphamide, sulfa drugs, etc.) well-known to those
skilled in the art may also be utilized.

A preferred pharmaceutical composition of the
present invention comprises the use of the subject chimeric
antibodies in immunotoxins. Immunotoxins are characterized
35   by two components and are particularly useful for killing
selected cells in vitro or in vivo. One component is a
cytotoxic agent which is usually fatal to a cell when

attached or absorbed. The second component, known as the
"delivery vehicle," provides a means for delivering the toxic
agent to a particular cell type, such as cells comprising a
carcinoma. The two components are commonly chemically bonded
together by any of a variety of well-known chemical
5   procedures. For example, when the cytotoxic agent is a
protein and the second component is an intact immunoglobulin,
such as a chimeric antibody, the linkage may be by way of
heterobifunctional cross-linkers, e.g., SPDP, carbodiimide,
glutaraldehyde, or the like. Production of various
10   immunotoxins is well-known with the art, and can be found,
for example in "Monoclonal Antibody-Toxin Conjugates: Aiming
the Magic Bullet," Thorpe et al, Monoclonal Antibodies in
Clinical Medicine, Academic Press, pp. 168-190 (1982), which
is incorporated herein by reference.
15   A variety of cytotoxic agents are suitable for use
in immunotoxins. Cytotoxic agents can include
radionuclides, such as Iodine-131, Yttrium-90, Rhenium-188,
and Bismuth-212; a number of chemotherapeutic drugs, such as
vindesine, methotrexate, adriamycin, and cisplatinum; and
20   cytotoxic proteins such as ribosomal inhibiting proteins,
pokeweed antiviral protein, abrin and ricin (or their A-
chains, diphtheria toxin A-chains, Pseudomonas exotoxin A,
etc.) or an agent active at the cell surface, such as the
phospholipase enzymes (e.g., phospholipase C). (See
25   generally, "Chimeric Toxins," Olsnes and Phil, Pharmac.
Ther., 25:355-381 (1982), and "Monoclonal Antibodies for
Cancer Detection and Therapy," eds. Baldwin and Byers, pp.
159-179, 224-266, Academic Press (1985), both of which are
incorporated herein by reference.)
30   The delivery component of the immunotoxin will
include the chimeric antibodies of the present invention.
Intact chimeric immunoglobulins or their binding fragments,
such as Fab, F(ab$_2$), etc., are preferably used. Typically,
the chimeric antibodies in the immunotoxins will be of the
35   human IgM or IgG isotype, but other mammalian constant
regions may be utilized as desired.
               The chimeric antibodies and pharmaceutical

compositions thereof of this invention are particularly
useful for parenteral administration, _i.e._, subcutaneously,
intramuscularly or intravenously. The compositions for
parenteral administration will commonly comprise a solution
of the antibody or a cocktail thereof dissolved in an accept-
5   able carrier, preferably an aqueous carrier. A variety of
aqueous carriers can be used, _e.g._, water, buffered water,
0.4% saline, 0.3% glycine and the like. These solutions are
sterile and generally free of particulate matter. These
compositions may be sterilized by conventional, well known
10   sterilization techniques. The compositions may contain
pharmaceutically acceptable auxiliary substances as required
to approximate physiological conditions such as pH adjusting
and buffering agents, toxicity adjusting agents and the like,
for example sodium acetate, sodium chloride, potassium
15   chloride, calcium chloride, sodium lactate, etc. The
concentration of antibody in these formulations can vary
widely, _i.e._, from less than about 0.5%, usually at or at
least about 1% to as much as 15 or 20% by weight and will be
selected primarily based on fluid volumes, viscosities, etc.,
20   in accordance with the particular mode of administration
selected.

        Thus, a typical pharmaceutical composition for
intramuscular injection could be made up to contain 1 ml
sterile buffered water, and 50 mg of antibody. A typical
25   composition for intravenous infusion could be made up to
contain 250 ml of sterile Ringer's solution, and 150 mg of
antibody. Actual methods for preparing parenterally
administrable compositions will be known or apparent to those
skilled in the art and are described in more detail in, for
30   example, _Remington's Pharmaceutical Science_, 15th Ed., Mack
Publishing Company, Easton, Pennsylvania (1980), which is
incorporated herein by reference.

        The antibodies of this invention can be lyophilized
for storage and reconstituted in a suitable carrier prior to
35   use. This technique has been shown to be effective with
conventional immune globulins and art-known lyophilization
and reconstitution techniques can be employed. It will be

appreciated by those skilled in the art that lyophilization
and reconstitution can lead to varying degrees of antibody
activity loss (e.g., with conventional immune globulins, IgM
antibodies tend to have greater activity loss than IgG
antibodies) and that use levels may have to be adjusted to
5   compensate.

The compositions containing the present human
chimeric antibodies or a cocktail thereof can be administered
for the prophylactic and/or therapeutic treatments. In
therapeutic application, compositions are administered to a
10   patient already, in an amount sufficient to cure or at least
partially arrest the infection and its complications. An
amount adequate to accomplish this is defined as a
"therapeutically effective dose." Amounts effective for this
use will depend upon the severity of the infection and the
15   general state of the patient's own immune system, but
generally range from about 1 to about 200 mg of antibody per
dose, with dosages of from 5 to 25 mg per patient being more
commonly used. It must be kept in mind that the materials of
this invention may generally be employed in serious disease
20   states, that is life-threatening or potentially life-
threatening situations. In such cases, in view of the
minimization of extraneous substances and the lower
probability of "foreign substance" rejections which are
achieved by the present human chimeric antibodies of this in-
25   vention, it is possible and may be felt desirable by the
treating physician to administer substantial excesses of
these antibodies.

In prophylactic applications, compositions
containing the present antibodies or a cocktail thereof are
30   administered to a patient not already in a disease state to
enhance the patient's resistance. Such an amount is defined
to be a "prophylactically effective dose." In this use, the
precise amounts again depend upon the patient's state of
health and general level of immunity, but generally range
35   from 0.1 to 25 mg per dose, especially 0.5 to 2.5 mg per
patient.

Single or multiple administrations of the
compositions can be carried out with dose levels and pattern
being selected by the treating physician. In any event, the
pharmaceutical formulations should provide a quantity of the
antibody(ies) of this invention sufficient to effectively

5   treat the patient.

Chimeric antibodies of the present invention can
further find a wide variety of utilities _in vitro_. By way of
example, the chimeric antibodies can be utilized for T-cell
typing, for isolating specific IL-2 receptor bearing cells or

10   fragments of the receptor, for vaccine preparation, or the
like.

For diagnostic purposes, the chimeric antibodies
may either be labeled or unlabeled. Unlabeled antibodies can
be used in combination with other labeled antibodies (second

15   antibodies) that are reactive with the chimeric antibody,
such as antibodies specific for human immunoglobulin constant
regions. Alternatively, the chimeric antibodies can be
directly labeled. A wide variety of labels may be employed,
such as radionuclides, fluorescers, enzymes, enzyme

20   substrates, enzyme cofactors, enzyme inhibitors, ligands
(particularly haptens), etc. Numerous types of immunoassays
are available and are well known to those skilled in the art.

Kits can also be supplied for use with the subject
antibodies in the protection against or detection of a

25   cellular activity or for the presence of a selected antigen.
Thus, the subject antibody composition of the present
invention may be provided, usually in a lyophilized form in a
container, either alone or in conjunction with additional
antibodies specific for the desired cell type. The

30   antibodies, which may be conjugated to a label or toxin, or
unconjugated, are included in the kits with buffers, such as
Tris, phosphate, carbonate, etc., stabilizers, biocides,
inert proteins, _e.g._, serum albumin, or the like, and a set
of instructions for use. Generally, these materials will be

35   present in less than about 5% wt. based on the amount of
active antibody, and usually present in total amount of at
least about 0.001% wt. based again on the antibody

concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% wt. of the total composition. Where a second antibody capable of binding to the chimeric antibody is

5 employed in an assay, this will usually be present in a separate vial. The second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above.

The following examples are offered by way of

10 illustration, not by limitation.

15

20

25

30

35

18

EXPERIMENTAL

Construction of Plasmids

1. Construction began with the plasmid pKcatH described in
    the literature (Garcia, J.V. et al., Nature 332:383-385
    5   (1986); Fig. 3). This plasmid has the following parts;
        clockwise:

    a. A 700 bp fragment containing the mouse
        immunoglobulin heavy chain enhancer (E_H in the Fig.
        3).

    10 b. An 1100 base pair (bp) fragment from the mouse
        immunoglobulin light chain kappa gene MOPC 41,
        containing its promoter. There is a Bgl II site 25
        bp after the transcription startsite of this
        promoter.

    15 c. The bacterial CAT gene (800 bp).

    d. A splice and polyadenylation signal from the animal
        virus SV40 (850 bp).

    e. Another part of SV40 containing its origin of
        replication (700 bp);

    20 f. Part of the plasmid pBR322, extending from the Sph
        I site to the Eco R1 site of the plasmid pML1
        (Lusky, M and Botchan, M. Nature 293:79-81; 2300
        bp) including the Amp gene and origin of
        replication.

    25

2. pKcatH was cut with Bgl II, and the ends filled in with
    Klenow polymerase. An Xba I linker, having the sequence
    GCTCTAGAGC, was inserted at the filled-in Bgl II site.
    The resulting plasmid is called pKcatH - Xba.

30

3. pKcatH - Xba was cut partially with Xho II, run on an
    agarose gel, and full-length linear plasmid (i.e.,
    plasmid cut exactly once with Xho II) was isolated. The
    DNA was cut with Bam HI, run on a gel and the 5600 bp
    35 fragment isolated. Because of its size, this fragment
    had to extend from the Bam site to the Xho II site at
    the end of the CAT gene (Fig. 3). The fragment was

ligated by itself. The resulting plasmid is called
pKcatH - Xba - BX. It is similar to pKcatH but has an
Xba I site in place of the Bgl II site and is missing
the Xho II - Bam HI SV40 fragment (Fig. 4).

5   4.   pKcatH - Xba - BX was cut partially with Eco RI, run on
an agarose gel, and full-length linear plasmid was
isolated. This DNA was cut with Bam HI, and the 2600 bp
fragment isolated. This fragment extended from the Eco
R1 site before E_H to the Bam HI site. The plasmid
10   pSV2gpt, described in the literature (Mulligan, R.C. and
Berg, P., <u>Proc. Nat. Acad. Sci. USA</u> <u>78</u>:2072-2976
(1980)), was cut with Eco R1 and Bam HI and the large
Eco RI - Bam HI fragment ligated to the Eco RI - Bam HI
fragment from pKcatH - Xba - BX. The resulting plasmid
15   is called pSV2gpt - E_H - κ, (Fig. 5).

5.   The plasmid pSV2neo (Southern, P.J. and Berg, P. <u>J. Mol.
App. Genet.</u> <u>1</u>:327-341 (1982)), was cut with Eco RI and
Bam HI, and the large Eco RI - Bam HI fragment ligated
20   to the same Eco RI - Bam HI fragment from pKcatH - Xba -
BX used in (4). The resulting plasmid is called pSV2neo
- EH - κ, which is like pSV2gpt - EH - κ, but has the
Neo gene in place of the Gpt gene.

25   6.   pSV2gpt - E_H - κ was cut with Xba I and Bam HI and the
ends filled in with Klenow polymerase. A fragment of
the cloned human κ constant segment gene (Hieter, P.A.
et al., <u>Cell</u> <u>22</u>:197-207 (1980)) was purified, extending
from a Hind III site 336 bp before the coding region, to
30   an Xba I site about 800 bp beyond the coding region, and
the ends filled in. The two fragments were ligated
together, and a plasmid selected in which the Hind III
site of the second fragment was joined to the Xba I site
and the Xba I site of the second fragment to the Bam HI
35   site. Because of the sequences of these sites, this
recreated an Xba I site and a Bam HI site. The new
plasmid is called pVκ1 (Fig. 6).

20

7. An Xba I fragment containing the VJ region of the cloned
anti-Tac light chain gene was prepared by in vitro
mutagenesis (see, below). pVκ1 was cut with Xba I,
treated with phosphatase, and ligated with the Xba I
fragment. A plasmid was selected in which the VJ region
5   had the same orientation as the following C region, and
called pLTAC2 (Fig. 7).

8. pSV2neo - E_H - κ was cut with Xba I and Bam HI and the
ends filled in with Klenow polymerase. A 2800 bp
10   fragment containing the human Cγ1 gene was purified from
the phage HG3A (Ellison, J.W. et al., Nucleic Acids Res.
10:4071-4079 (1982)), extending from a Hind III site 210
bp before the CH1 exon to a Pvu II site about 1100 bp
after the CH3 exon, and the ends filled in. The two
15   fragments were ligated together, and a plasmid selected
in which the Hind III site of the second fragment was
joined to the Xba I site and the Pvu II site of the
second fragment to the Bam HI site. Because of the
sequences of these sites, this recreated an Xba I site
20   and a Bam HI site. The new plasmid is called pVγ1neo
(Fig. 8).

9. pSV2neo - E_H - κ was cut with Xba I and Bam HI and the
ends filled in with Klenow polymerase. A 3600 bp
25   fragment containing the human Cγ3 gene (Takahashi, N. et
al., Cell 29:671-679 (1982)) was purified extending from
a Hind III site 210 bp before the CH1 exon to a Pvu II
site about 1100 bp after the CH3 exon, and the ends
filled in. The two fragments were ligated together, and
30   a plasmid selected in which the Hind III site of the
second fragment was joined to the Xba I site and the Pvu
II site of the second fragment to the Bam HI site.
Because of the sequences of these sites, this recreated
an Xba I site and a Bam HI site. The new plasmid is
35   called pVγ3neo and is identical to pVγ1neo except it has
the Cγ3 gene instead of Cγ1.

10. An Xba I fragment containing the VJ region of the cloned
    anti-Tac heavy china gene was prepared by in vitro
    mutagenesis (see, below). pVγ1neo was cut with Xba I,
    treated with phosphatase, and ligated with the Xba I
    fragment. A plasmid was selected in which the VJ region
    had the same orientation as the following C region, and
    called pHTAC.

11. Three additional plasmids were prepared respectively
    from pVγ1neo, pVγ3neo and pHTAC, called respectively
    pVγ1, pVγ3 and pGTAC1. In each case, the original
    plasmid was cut with Hind III and Bam HI, and the large
    Hind III - Bam HI fragment purified. The plasmid
    pXBohph containing the Hyg gene (Blochlinger, K. and
    Diggelmann, H. Mol. Cell. Biol. 4:2929-2931 (1984)) was
    cut with Hind III and Bam HI and a 1600 bp fragment
    containing the Hyg gene purified. The fragments from
    the original plasmids were each ligated to the pXbohph
    fragment. pVγ1 is shown in Fig. 9 and pGTAC1 in Fig.
    10.

12. pHTAC was cut with Xba I and the small Xba I fragment,
    containing the heavy VJ region, purified. pVγ3 was cut
    with Xba I, treated with phosphatase, and ligated with
    the small Xba I fragment. A plasmid was selected in
    which the VJ region had the same orientation as the
    following C region, and called pGTAC3. It is similar to
    pGTAC1, but has the Cγ3 region instead of the Cγ1
    region.

Cloning of Light and Heavy Chain cDNA.

mRNA was extracted from approximately 10-8 ascites
cells of the anti-Tac hybridoma by the guanidium
isothiocyanate method followed with poly A selection on
Hybond-mAP paper (Amersham). cDNA was prepared by the method
5   of Gubler and Hoffman (Gubler, U. and Hoffman, B.J. Gene
25:263-269 (1983)), treated with Eco R1 methylase, ligated to
Eco RI linkers, cloned into λgt10 arms (Promega Biotec),
packaged (Strategene packaging extract) and plated on C600Hfl
cells. Oligonucleotides respectively 43 and 37 nucleotides
10   long that hybridized to the 5' ends of the mouse Cκ and Cγ1
segments were synthesized (Applied Biosystems Model 380B DNA
synthesizer). The oligonucleotides were 5' end-labelled and
used to screen the plaques (Maniatis, et al., Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Press,
15   (1982), which is incorporated herein by reference).

Approximately 10,000 plaques were screened with the
oligonucleotide probes. About 100 plaques were positive for
the γ probe and 40 for the γ probe.

The cDNA inserts from 4 κ positive and 4 γ2a
20   positive phage were subcloned into the Eco R1 sites of pUC19
and M13mp19. Partial sequencing by the dideoxy method
(Sanger, F. et al., Proc. Nat. Acad. Sci. USA 74:5463-5467
(1977)) showed that two of the κ isolates had one sequence,
and the other two had another sequence. In one pair, a κ V
25   gene segment was joined to the JK2 segment out of its reading
frame. In addition, the conserved Cys at position 23 was
absent in this V segment, and the sequences of the two
isolates differed slightly. Presumably, these clones were
the result of an aberrant joining event in one κ allele,
30   which continued to undergo somatic mutation after the
formation of the hybridoma.

The VJ segments of the other pair of κ clones were
sequences completely and were identical (Fig. 1). This light
chain uses the JK5 segment and contains all the amino acid
35   residues conserved in mouse κ light chains (Kabat, E. A. et
al., Sequences of Proteins of Immunological Interest,
particularly pg. 45 et seq, all of which is incorporated

herein by reference).

Partial sequencing of the four γ2a clones showed
they were from the same gene. The VJ segments of two were
sequenced completely and had no differences. This heavy
chain (Fig. 2) uses the JH2 segment and is of subgroup II

5   (Kabat, E.A. et al., supra, at pgs. 121-127). The sequence
is somewhat unusual because it contains no detectable D
segment and has an N region containing 10 Gs. As both
alleles of the κ light chain were accounted for and only one
heavy chain sequence was detected, we tentatively assigned

10   these sequences to the anti-Tac antibody genes.

Preparation of the Chimeric Genes

Plasmid vectors were prepared for the construction
and expression of chimeric light and heavy chain genes as

15   described above. The plasmid pVκ1 (Fig. 6) contains the
human κ genomic C segment, including 336 bp of the preceding
intron and the poly A signal. It also contains a strong
promoter sequence from the MOPC 41 κ gene, and the heavy
chain enhancer sequence. There is a unique Xba I site

20   between the promoter and the C intron. The plasmid also
contains the gpt gene for selection. Two other very similar
plasmids were prepared by using the human γ1 and γ3 C regions
in place of the κ C region. In each case, the region
inserted between the Xba I and Bam HI sites extended form

25   about 210 bp 5' of the CH1 exon to about 1100 bp 3' of the
CH3 exon. In addition, the gpt gene was replaced with the
hyg gene to confer resistance to hygromycin.

Our strategy was to insert the VJ region from the
anti-Tac κ cDNA, followed by a splice donor signal, at the

30   Xba I site of pVκ1. Doing so would create a chimeric κ gene,
with a synthetic intron between the mouse VJ and human Cκ
segments. For this purpose, we devised a form of primer-
directed mutagenesis (Fig. 11). The κ Eco R1 cDNA clone was
moved into a variant of M13mp11, in which the Xba 1 and Eco

35   R1 sites in the polylinker were abuting. An oligonucleotide
was synthesized, of which the first 22 residues hybridized to
the last 22 bp of the JK5 segment. The next 16 nucleotides

24

were the same as the sequence that follows JK5 in mouse
genomic DNA, and therefore included a splice donor signal.
The final nucleotides of the oligo consisted of an Xba I site
followed by a short irrelevant sequence.

This oligonucleotide was hybridized to the M13
5   phage DNA containing the κ cDNA and extended with Klenow
polymerase (Fig. 3). The DNA was denatured and hybridized to
a "reverse primer," which represents M13 DNA 5' to the cDNA
insert. The reverse primer was extended, and the DNA cut
with Xba I. The Xba I fragment consisting of the extended VJ
10   segment of the cDNA was purified, and cloned in the
correction orientation into the Xba I site of pVκ1 to obtain
the plasmid pLTAC2 (Fig. 7). Hence, the final chimeric κ
gene has a VJ-C intron, of which the first 14 bp and last 209
bp are respectively the same as in mouse and human genomic
15   DNA, as verified by direct sequencing of the construct. The
gene is transcribed from a κ promoter, stimulated by the
heavy chain enhancer. Based on results obtained with deleted
introns, we expected that the intron would be correctly
spliced from the transcribed RNA.
20   In an analogous manner, the VJ region from the
anti-Tac γ2a heavy chain cDNA, followed by a splice donor
signal, was inserted into the Xba I site of pVγ1neo. The
resulting plasmid pHTAC contains a chimeric heavy chain gene,
with a synthetic intron between the mouse VJ and human Cγ1
25   segments. The additional plasmids pGTAC1 and pGTAC3,
containing the Hyg gene and chimeric heavy genes with the
human Cγ1 Cγ3 constant regions respectively, were constructed
as described above (Fig. 10).

30

35

Details of Insertion of VJ cDNA Regions Into Plasmids

    RF DNA of the phage M13mp11 was cut with Eco R1 and
Xba I, the ends were filled-in, and the DNA ligated was
ligated and transformed into JM101 cells. A plaque was
picked and the DNA was sequenced to verify that the ends of
5   the DNA had joined correctly, recreating the Eco R1 and Xba I
sites with the intervening DNA segment deleted. This phage
is designated M13mp11D. Eco R1 fragments containing the
anti-Tac light and heavy chain cDNAs were separately cloned
into the Eco R1 site of M13mp11, so that their 5' ends abuted
10 the Xba I site. The resulting phage are respectively denoted
M13mp11L and M13mp11H.

    The following 48-nucleotide long primer was
synthesized and gel-purified:
CCAGAATTCTAGAAAGTGTACTTACGTTTCAGCTCCAGCTTGGTCCC. From the
15 3' end, the first 22 residues of the primer are the same as
the last 22 bp of the JK5 segment (non-coding strand). The
next 16 nucleotides are the same as the sequence that follows
JK5 in mouse genomic DNA and therefore includes a splice
donor signal (abbreviated SD in Fig. 11). The final
20 nucleotides of the oligo consist of an Xba I site followed by
a short irrelevant sequence. Approximately 1 ug of single-
stranded M13mp11L DNA was mixed with 50 ng of primer in 35 ul
of 10 mM Tris, pH 7.4, 60 mM NaCl, 10 mM $MgCl_2$ and incubated
for 15 min at 50`C and then 15 min at 23`C. 4 ul of a
25 solution of 200 uM each dNTP was added, together with 5u
Klenow polymerase. The solution was incubated for 30 minutes
at 37`C. 50 ng of the "reverse primer" AACAGCTATGACCATG (New
England Biolabs), which can hybridize to the newly
synthesized strand upstream of the Xba I site (Fig. 11), was
30 added. The solution was incubated at 95`C for 3 min and put
on ice. An additional 4 ul of 200 uM each dNTP and 5u Klenow
polymerase was added, and the solution incubated for 30
minutes at 37`C. The solution was extracted with phenol-
chloroform, precipitated with ethanol, resuspended, and
35 digested with 20u Xba I. The digested DNA was run on a 4%
polyacrylamide gel and visualized with ethidium bromide. In
addition to high molecular weight DNA, an approximately 400

26

bp fragment was visible, corresponding to the VJ region of
the light chain cDNA with a "tail" (Fig. 11). The fragment
was cloned directly into the Xba I site of pVκ1 in the
correct orientation.

The following 50-nucleotide long primer was

5   synthesized and gel-purified:
CCAGAATTCTAGAGGTTTTAAGGACTCACCTGAGGAGACTGTGAGAGTGG. From the
3' end, the first 21 residues of the primer are the same as
the last 21 bp of the JH2 segment (non-coding strand). The
next 19 nucleotides are the same as the sequence that follows

10   JH2 in mouse genomic DNA and therefore includes a splice
donor signal. The final nucleotides of the oligo consist of
an Xba I site followed by a short irrelevant sequence. This
primer was hybridized to M13mp11H DNA following the same
protocol as above, in order to synthesize a fragment

15   containing the VJ region of the heavy chain cDNA. The
fragment was cloned directly into the Xba I site of pVγ1neo
in the correct orientation.

Chimeric Antibody Specificity

20   CR2-2 and CEM cells are human T cell lines that are
respectively positive and negative for surface expression of
the IL2 receptor (IL2R). Whole CR2-2 cells were used to
demonstrate binding specificity of the chimeric antibody in
an ELISA assay, and CEM cells were used as a negative

25   control.

Antibody to be tested was prepared in several ways.
Anti-Tac monoclonal antibody, supplied by T. Waldmann, was
purified from mouse ascites by passage through a DEAE-dextran
column. The cell line L40H4, created by transfecting SP2/0

30   cells with the chimeric light and gamma 1 heavy chain
plasmids pLTAC2 and pGTAC1 (described above), was injected
into mice to form an ascites. From 3 mls of ascites fluid,
650 μg of chimeric gamma 1 antibody was purified by passage
through a column of Baker Abx and a size exclusion column.

35   Also, to detect antibody production in tissue culture, 10^6
cells each of L40H4 and the cell lines 51.3 and L40H2 (which
had been created by transfecting SP2/0 with pLTAC2 and the

gamma 3 heavy chain plasmid pGTAC3 described before) and the non-producing line Sp2/0 itself, were plated in 1 ml of DME medium each. The media supernatent, containing any secreted chimeric antibodies, was harvested after 24 hr. and used directly in the assay,

Cultured cells of each type were washed in FACS buffer (0.1% BSA, .01% sodium azide in Dulbecco's phosphate buffered saline). 2×10^6 cells were mixed with either purified antibody in 20 μl FACS buffer or 20 μl media supernatent from the transfected cell lines, and incubated on ice for 2 hr. The cells were washed 3 times with 1 μl of FACS buffer (being collected by brief centrifugation after each wash). The cells that had been incubated with anti-Tac antibody (or no antibody as a control) were mixed with 0.5 μl peroxidase-conjugated goat anti-mouse antibody (Fab)$'_2$ fragment (Tago Immunologicals, Burlingame, California) in 20 μl FACS buffer, and the cells that had been incubated with chimeric antibody were mixed with 0.5 μl peroxidase-conjugated goat anti-human gamma chain (Fab)$'_2$ fragment (Tago) in 20 μl FACS buffer. The cells were incubated for 30 min on ice and then washed 3 times with FACS buffer. They were then mixed with 100 μl peroxidase development solution and incubated for 5 min at room temperature. The cells were spun out and the supernatents were transferred to a 96-well plate and the OD's determined in an ELISA reader. The OD's at 414 nm for the cells treated with each antibody are given in Table 1.

As expected the anti-Tac antibody itself bound to the IL2R+ CR2-2 cells but not to the IL2R- CEM cells. An equal amount of purified gamma 1 chimeric antibody gave an equivalent amount of binding to the CR2-2 cells as the anti-Tac, and also failed to bind to the CEM cells. All the supernatants from both the chimeric antibody producing cells bound to the CR2-2 cells. As additional negative controls, the 51.3 supernatant did not bind to the CEM cells, and supernatant from the parental SP2/0 cells did not bind the CR2-2 cells.

In combination with the derivation of the light and

28

heavy chain genes from the anti-Tac hybridoma, these results
show that the chimeric antibodies retained specificity for
the human IL2R.

5

10

15

20

25

30

35

TABLE 1

Whole-Cell ELISA Assay of Chimeric Antibodies

	CR2-2 cells (IL2R +)	CEM cells (IL2R −)
Mouse Gamma 2a		
none	.037	−
anti-Tac (100ng)	.679	.024
Human Gamma 1		
none	.084	−
purified ascites (100ng)	.641	.044
L40H4 (20 μl sup.)	.481	−
Human Gamma 3		
51.3 (20 μl sup.)	.381	.038
L40H2 (20 μl sup.)	.932	−

To quantitate the rate of secretion of the chimeric antibodies, an ELISA assay was performed, using standard methods. The results are presented in Table 2. About 10^6 cells each of the chimeric gamma 1 secreting line L40H0 and the chimeric gamma 3 secreting line 51.3 were plated in 1 ml

5   of DME medium with 5% fetal calf serum, and the supernatents collected after 24 hr. A 96-well plate was coated with goat anti-human antibodies (Tago Immunologicals). Different wells were incubated with increasing known amounts of gamma 1 chimeric antibody (purified from ascites) and with 1 μl of

10 the chimeric antibody supernatents. Briefly, the plate was washed, incubated with peroxidase-conjugated goat anti-human gamma chain antibody, washed again, incubated with peroxidase developing solution and the OD's at 414 nm determined in an ELISA reader. By comparison with the standard curve from the

15 purified antibody, the media supernatants contained respectively about 8 and 7 ng per μl, that is the cells secreted 8 and 7 μg antibody per 10^6 cells per 24 hr.

20

25

30

35

TABLE 2

Rate of Chimeric Antibody Secretion

OD_{414}

Purified gamma 1 chimeric

3 ng	.426
4 ng	.535
6 ng	.734
8 ng	1.004
L40H4 (1 μl sup.)	1.014
51.3 (1 μl sup.)	.845

32

The mixed lymphocyte reaction is a model for
transplant rejection and was used to analyze the
effectiveness of the chimeric anti-Tac antibodies. The
experiments shown in Table 3 below were performed by standard
methods (see, e.g., Strong, D.M. et al., In Vitro Stimulation
of Murine Spleen Cells Using a Microculture System and a
Multiple Automated Sample Harvester, J. Immunol. Meth., 2:279
(1973)). Briefly, human peripheral blood lymphocytes from
two unrelated human donors were purified. The lymphocytes
from the two donors were incubated in wells of a 96-well
plate, either separately, mixed together, or mixed together
with 1 μg/ml of the indicated antibody added each day. When
mixed together, the T-cells recognize each other as foreign,
as T cells recognize an organ transplant as foreign. They
therefore proliferate, as measured by uptake of 3H-labeled
thymidine after three days. The numbers in Table 3 are the
average thymidine uptake in cpm from triplicate wells ± the
standard deviation. Addition of either the original anti-Tac
antibody or either of the chimeric antibodies strongly
inhibits proliferation of the cells (percent inhibition shown
in parentheses), by binding to the IL2R. This prevents IL2
from binding to the IL2R, which is required for T-cell
proliferation. These experiments show that the chimeric
antibody can be used to reduce the response of T-cells to
foreign cells and may therefore have medical applications in
preventing transplant rejection.

33

TABLE 3

Anti-IL2R Antibody Inhibition of Mixed Lymphocyte Reaction

	Exp. 1	Exp. 2
Donor A	510 ± 292	151 ± 5
Donor B	901 ± 38	712 ± 29
A + B	11740 ± 1593	19806 ± 2034
A + B + anti-Tac	4262 ± 346 (73%)	7311 ± 461 (66%)
A + B + Human Gamma 1	4126 ± 370 (74%)	6721 ± 981 (69%)
A + B + Human Gamma 3	-	6423 ± 423 (71%)

5

10

15

20

25

30

35

From the foregoing, it will be appreciated that the chimeric antibodies of the present invention offer numerous advantages of other human IL-2 receptor-specific antibodies. In comparison to anti-Tac mouse monoclonal antibodies, the present human chimeric antibodies can be
5 more economically produced and contain substantially less foreign amino acid sequences. This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.

Although the present invention has been described in
10 some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

15

20

25

30

35

CLAIMS

1.   A method of treating T-cell mediated disorders
in a human patient, said method comprising administering to
said patient a therapeutically effective dose of a mouse
5   variable/human constant region chimeric antibody
composition specifically reactive with IL-2 receptors on
human T-cells.

2.   A method according to Claim 1, wherein the
10 mouse variable region comprises the entire variable region
from heavy and light chains of an anti-Tac monoclonal
antibody as produced by the cell line designated A.T.C.C.
Accession No. CRL 9688.

15   3.   A method according to Claim 1, wherein at least
one of the mouse variable regions is joined with a
naturally-associated mouse J segment.

4.   A method according to Claim 1, wherein the
20 human light chain constant region comprises a κ chain
constant region.

5.   A method according to Claim 1, wherein the
human light chain constant region comprises a γ_1 or
25 γ_3 chain constant region.

6.   A method according to Claim 1, wherein the
composition comprises the chimeric antibody complexed with
a cytotoxic agent.
30

7.   A method according to Claim 1, wherein the
cytotoxic agent is a ribosomal inhibiting protein, a
radionuclide or cytotoxic agent active at cell surfaces.

35

8.   A chimeric antibody capable of binding to a
human IL-2 receptor epitope, said antibody having two pairs
of light chain/heavy chain complexes, wherein at least one
pair has chains comprising mouse variable region and human
constant region segments.

5

9.   A chimeric antibody according to Claim 8,
wherein the mouse variable region is adjacent to a
naturally associated J segment.

10

10.   A chimeric antibody according to Claim 8, which
inhibits the binding of monoclonal antibodies secreted by
the cell line designated A.T.C.C. Accession No. CRL 9688.

11.   A chimeric antibody according to Claim 10,
15 wherein at least one variable region comprises the amino
acid sequence of a variable region of the anti-Tac
monoclonal antibody.

12.   A chimeric antibody according to Claim 8, which
20 was produced in a myeloma or hybridoma cell.

13.   A chimeric antibody according to Claim 8, which
was expressed in a myeloma cell from a transfected DNA
sequence comprising a mouse cDNA segment joined to a human
25 genomic DNA segment.

14.   A chimeric antibody according to Claim 8
complexed with a cytotoxic agent or signal agent.

30
15.   A heavy immunoglobulin chain comprising a human
heavy chain constant region and a variable chain region
which is substantially identical to a monoclonal antibody
heavy chain variable region secreted by the cell line
designated A.T.C.C. Accession No. CRL 9688.

35

16. A heavy immunoglobulin chain according to Claim 15, wherein the variable and constant region are joined by a mouse J segment.

17. A light immunoglobulin chain comprising a human
5 light chain constant region and a variable chain region which is substantially identical to a monoclonal antibody light chain variable region secreted by the cell line designated A.T.C.C. Accession No. CRL 9688.

10 18. A polynucleotide molecule comprising a first sequence coding for a human immunoglobulin constant region and a second sequence coding for a mouse immunoglobulin variable region, wherein said second sequence encodes substantially for one of the amino acid sequences of
15 Figures 1 or 2.

19. A cell line transfected with a polynucleotide of Claim 18.

20 20. The cell line designated A.T.C.C. Accession No. CRL 9688.

21. A DNA segment encoding a portion of an immunoglobulin light chain, said segment comprising at
25 least about 30 contiguous nucleotides from the sequence of Figure 1.

22. A DNA segment according to Claim 21, wherein the segment encodes a full length light chain variable
30 region substantially homologous to the sequence in Figure 1.

23. A DNA segment encoding a portion of an immunoglobulin heavy chain, said segment comprising at
35 least about 30 contiguous nucleotides from the sequence of Figure 2.

24. A DNA segment according to Claim 23, wherein
the segment encodes a full length heavy chain variable
region substantially homologous to the sequence in
Figure 2.

5   25. An expression vector comprising a heterologous
promoter operably linked to a DNA segment according to
Claim 21 or 23.

26. An immortalized cell line transformed with an
10 expression vector according to Claim 25.

27. A protein composition comprising at least about
ten contiguous amino acids from the protein sequence of
Figure 1 or Figure 2 fused to a heterologous polypeptide.
15

28. A protein composition according to Claim 27,
wherein the heterologous polypeptide is an immunoglobulin
constant region.

20   29. A protein composition according to Claim 27,
wherein the protein is glycosylated.

30. A recombinantly produced antibody exhibiting
substantially the same antigen binding profile as an
25 immunoglobulin secreted by a cell line designated A.T.C.C.
Accession No. CRL 9688.

30

35

```
        10          20          30          40          50          60
AAATTCAAAGACAAAATGCATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCC
              MetHisPheGlnValGlnIlePheSerPheLeuLeuIleSerAla

        70          80          90         100         110         120
TCAGTCATAATGTCCAGAGGACAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCA
SerValIleMetSerArgGlyGlnIleValLeuThrGlnSerProAlaIleMetSerAla

       130         140         150         160         170         180
TCTCCAGGGGAGAAGGTCACCATAACCTGCAGTGCCAGCTCAAGTATAAGTTACATGCAC
SerProGlyGluLysValThrIleThrCysSerAlaSerSerSerIleSerTyrMetHis

       190         200         210         220         230         240
TGGTTCCAGCAGAAGCCAGGCACTTCTCCCAAACTCTGGATTTATACCACATCCAACCTG
TrpPheGlnGlnLysProGlyThrSerProLysLeuTrpIleTyrThrThrSerAsnLeu

       250         260         270         280         290         300
GCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGATCTGGGACCTCTTACTCTCTCACA
AlaSerGlyValProAlaArgPheSerGlySerGlySerGlyThrSerTyrSerLeuThr

       310         320         330         340         350         360
ATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCATCAAAGGAGTACTTAC
IleSerArgMetGluAlaGluAspAlaAlaThrTyrTyrCysHisGlnArgSerThrTyr

       370         380         390         400
CCACTCACGTTCGGTTCTGGGACCAAGCTGGAGCTGAAAC
ProLeuThrPheGlySerGlyThrLysLeuGluLeuLys
```

FIG.—1.

FIG.—3.

```
        10          20          30          40          50          60
GCATCCTCTCCACAGACACTGAAAACTCTGACTCACAATGGAAAGGCACTGGATCTTTCT
                                        MetGluArgHisTrpIlePheLe

        70          80          90         100         110         120
CTTCCTGTTTTCAGTAACTGCAGGTGTCCACTCCCAGGTCCAGCTTCAGCAGTCTGGGGC
uPheLeuPheSerValThrAlaGlyValHisSerGlnValGlnLeuGlnGlnSerGlyAl

       130         140         150         160         170         180
TGAACTGGCAAAACCTGGGGCCTCAGTGAAGATGTCCTGCAAGGCTTCTGGCTACACCTT
aGluLeuAlaLysProGlyAlaSerValLysMetSerCysLysAlaSerGlyTyrThrPh

       190         200         210         220         230         240
TACTAGCTACAGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGG
eThrSerTyrArgMetHisTrpValLysGlnArgProGlyGlnGlyLeuGluTrpIleGl

       250         260         270         280         290         300
ATATATTAATCCTAGCACTGGGTATACTGAATACAATCAGAAGTTCAAGGACAAGGCCAC
yTyrIleAsnProSerThrGlyTyrThrGluTyrAsnGlnLysPheLysAspLysAlaTh

       310         320         330         340         350         360
ATTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTGAGCAGCCTGACATTTGA
rLeuThrAlaAspLysSerSerSerThrAlaTyrMetGlnLeuSerSerLeuThrPheGl

       370         380         390         400         410         420
GGACTCTGCAGTCTATTACTGTGCAAGAGGGGGGGGGGTCTTTGACTACTGGGGCCAAGG
uAspSerAlaValTyrTyrCysAlaArgGlyGlyGlyValPheAspTyrTrpGlyGlnGl

       430         440
AACCACTCTCACAGTCTCCTCAG
yThrThrLeuThrValSerSer
```

## FIG._2.

FIG._4.   SUBSTITUTE SHEET

FIG._5.


FIG._6.

FIG._7.

FIG._8.

FIG._9.

FIG._I0.

FIG.__II.

INTERNATIONAL SEARCH REPORT

International Application PCT/US89/01578

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) [6]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(4): A61K 39/395; C12N 15/00; C12N 5/00; C07K 13/00; C07K 15/04.
US: 424/85.91; 424/85.8; 530/387; 435/68; 435/172.2; 435/240.27; 536/27.

II. FIELDS SEARCHED

Minimum Documentation Searched [7]

Classification System	Classification Symbols
U.S.	424/85.8; 424/85.91; 530/387; 530/388; 530/391; 530/808; 530/821; 530/825; 435/68; 435/70; 435/172.2; 435/172.3; 435/240.27; 435/240.2; 536/27; 935/32; 935/15.

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched [8]

Computer database searches on APS, Biosis.

III. DOCUMENTS CONSIDERED TO BE RELEVANT [9]

Category [*]	Citation of Document, [11] with indication, where appropriate, of the relevant passages [12]	Relevant to Claim No. [13]
Y	US, A, 4,664,911 (UHR et al), 12 May 1987 (12.05.87), see columns 2 to 6.	6,7,14
Y	EP, A, 0125023 (GENENTECH et al), 14 November 1984 (14.11.84), see pages 16-25, 28, 29, and 31 to 43.	1-30
Y	EP,A, 0173494 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY), 05 March 1986 (05.03.86), see pages 4-6 and 18-20.	1-30
Y	EP,A,0184187 (TEIJIN LIMITED), 11 June 1986 (11.06.86), see pages 8 to 23.	1-30
Y	WO,A, 86/01533 (CELLTECH LIMITED), 13 March 1986 (13.03.86), see pages 3-8 and 19-22.	1-30
Y	The Journal of Immunology, Vol.126, No.4, issued April 1981 (USA), UCHIYAMA et al, "A Monoclonal Antibody (ANTI-Tac) Reactive with Activated and Functionally Mature Human T Cells," see pages 1393 to 1397.	1-30

* Special categories of cited documents: [10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
10 July 1989	27 JUL 1989

International Searching Authority	Signature of Authorized Officer
ISA/US	Jeff P. Kushan

Form PCT/ISA/210 (second sheet) (Rev. 11-87)